/PRNewswire/ Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced the presentation of.
Full IDE Data Set Demonstrates Statistically Significant Reduction of All-Cause Mortality and Primary Major Adverse Events at 30 days with use of AMDS in Acute DeBakey Type I Dissections.
Interim Data Demonstrate Meaningful Reduction of All-Cause Mortality with AMDS
ATLANTA, Oct. 5, 2023 /PRNewswire/ Artivion, Inc. , a leading cardiac and vascular surgery company focused on aortic.
/PRNewswire/ Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today presented interim results from the.
Abstract Objectives: Non-alcoholic fatty liver disease (NAFLD) greatly affects cardiovascular disease, but evidence on the associations between NAFLD and markers of aortic calcification is limited. We aim to evaluate the association between NAFLD and aortic calcification in a cohort of Chinese adults using propensity score-matching (PSM) analysis. Methods: This prospective cohort study involved adults who underwent health-screening examinations from 2009 to 2016. NAFLD was diagnosed by abdominal ultrasonography at baseline, and aortic calcification was identified using a VCT LightSpeed 64 scanner. Analyses included Cox proportional-hazards regression analysis and PSM with predefined covariates (age, gender, marital and smoking status, and use of lipid-lowering drugs) to achieve a 1:1 balanced cohort. Results: Of 6,047 eligible participants, 2,729 (45.13%) were diagnosed with NAFLD at baseline, with a median age of 49.0 years [interquartile range: 44.0–55.0]. We selected 2,339 pairs o